How Biotech Startups Use Continuous Manufacturing to Cut Drug Costs

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

How Biotech Startups Use Continuous Manufacturing to Cut Drug Costs

無料で聴く

ポッドキャストの詳細を見る

For decades, drug manufacturing has been done in batches — a slow, expensive process that adds billions to healthcare costs. But a growing number of biotech startups are switching to continuous manufacturing, where ingredients flow through a closed system 24/7, producing drugs faster, cheaper, and more consistently. In this episode, Lucas and Luna explore how continuous manufacturing works, why the FDA is encouraging it, and which startups are leading the charge. They look at a specific case: how a small biotech called Continuus Pharmaceuticals cut production time for a common hypertension drug from weeks to hours, and how the approach could lower the cost of gene therapies and biologics. They also discuss the challenges — high upfront capital, regulatory hurdles, and the need for specialized talent — and why some incumbents are still reluctant to abandon batch processing. If these conversations are useful for what you're building or running, stick around for a quick honest moment about how this show stays ad-free. #ContinuousManufacturing #Biotech #DrugManufacturing #Pharmaceuticals #FDA #GenericDrugs #GeneTherapy #Biologics #CostReduction #Startups #ContinuusPharmaceuticals #BatchProcessing #RegulatoryScience #Business #BusinessPodcast #FexingoBusiness #BiotechBusiness #LifeSciences Keep every episode free: buymeacoffee.com/fexingo

まだレビューはありません